Abstract
BackgroundCrizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma. Its effects are thought to be mediated...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have